Team
DR. ALEXANDRE ZLOTTA, PRINCIPAL INVESTIGATOR
Dr. Alexandre Zlotta is Director of Uro-Oncology at Mount Sinai Hospital and Professor, Department of Surgery (Urology) at the University of Toronto.
Dr. Zlotta received his medical degree, urology training and PhD degree at the University of Brussels, Belgium. He was awarded the prestigious Matula Award, as the best European Academic Urologist in 2000. Dr. Zlotta is an uro-oncologic surgeon specializing in cancers (and other conditions) of the genitourinary organs (bladder, kidney, prostate, testes and related urological organs). He is currently performing research on prostate and bladder cancer.
Dr. Zlotta also serves as the Associate Editor for the Journal "bladder Cancer" and Assocciate Editor of "Frontiers in Oncology".
DR. NEIL FLESHNER, CO-INVESTIGATOR
Dr. Fleshner is a clinician scientist and uro-oncologist within the Division of Urology at Princess Margaret Cancer Care Center, University Health Network and is affiliated to Mount Sinai and Toronto General Hospitals. Dr. Fleshner completed his medical training from University of Toronto, followed by surgical residency and fellowship in urological surgery from University of Toronto and Memorial Sloan Kettering Cancer Center respectively. He also completed training in epidemiology from the Mailman School of Public Health at Columbia University.
As the Founder and Co-Director of the McCain GU BioBank, Dr. Fleshner envisioned early in his career the importance of longitudinal study design in urological cancer research and the importance of well characterized samples in such research projects. The current biobank is an offshoot of that early realization followed by years of meticulous work.
In addition to his surgical practice, Dr. Fleshner conducts research on urologic cancer prevention with an emphasis on prostate and bladder cancers. He has authored over 400 scientific papers and lectured at various national and international conferences.
Disclosure: Dr. Neil Fleshner is part of Verity Pharmaceuticals’ Scientific Advisory Board.
DR. SHARIQ HAIDER, CO-INVESTIGATOR
Dr. Shariq Haider is an infectious disease specialist with research interests including infections in immunocompromised hosts such as HIV, cancer patients, and bone marrow transplant patients. Much of Dr. Haider’s research includes studies on:
1) novel antiretroviral therapy in naïve and experienced HIV patients;
2) the epidemiology, diagnosis, and treatment of HCV coinfection in HIV infected patients
3) antifungal therapies in neutropenic hosts;
4) improving diagnostic methods in invasive fungal infections; and
5) novel antibacterial therapies.
DR. JAIME HERRERA-CACERES, CO-INVESTIGATOR
Dr. Jaime O. Herrera-Caceres is currently a clinical fellow at the University of Toronto and he is completing his Master in Medical Sciences at the Institute of Medical Sciences of the University of Toronto.
Dr. Herrera-Caceres received his medical degree from the Universidad Anahuac-Mayab in Merida, Mexico, and then completed his urology residency at the Institute of Medical Sciences and Nutrition “Salvador Zubiran” in Mexico City. Dr. Herrera-Caceres came to Toronto for his fellowship after completing the residency in 2017. Since then, he has focused mainly in urologic oncology doing both, research and clinical activity.
DR. WEI XU, CO-INVESTIGATOR
Dr. Xu is a biostatistician and Clinician Scientist at the Princess Margaret Cancer Center, and an Associate Professor in Biostatistics at the University of Toronto's Dalla Lana School of Public Health. As Principal-Investigator or co-Investigator, he has been involved in study design, data administration, statistical modeling development and data analysis on different clinical research and human genetic studies. He has published over 250 peer-reviewed papers in the field of statistics, bioinformatics, medical science and human genetics.